MX2016009621A - Derivados de fur0-3-carboxamida y metodos de uso. - Google Patents

Derivados de fur0-3-carboxamida y metodos de uso.

Info

Publication number
MX2016009621A
MX2016009621A MX2016009621A MX2016009621A MX2016009621A MX 2016009621 A MX2016009621 A MX 2016009621A MX 2016009621 A MX2016009621 A MX 2016009621A MX 2016009621 A MX2016009621 A MX 2016009621A MX 2016009621 A MX2016009621 A MX 2016009621A
Authority
MX
Mexico
Prior art keywords
methods
compounds
furo
carboxamide derivatives
formula
Prior art date
Application number
MX2016009621A
Other languages
English (en)
Inventor
Clapham Bruce
Vasudevan Anil
Woller Kevin
Sarris Katerina
Aguirre Ana
Scanio Marc
Cowart Marlon
Altenbach Robert
Liu Huaqing
Koenig John
SWINGER Kerren
VILLAMIL Clara
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2016009621A publication Critical patent/MX2016009621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Los compuestos de fórmula (I) y sales, ésteres, amidas, o formas radiomarcadas farmacéuticamente aceptables de los mismos, en donde R1, Z1, Z2, y n son como se definen en la descripción, son útiles en el tratamiento de condiciones o trastornos prevenidos por o mejorados por medio de Tropomiosina receptor quinasas (Trk). Se dan a conocer métodos para la fabricación de los compuestos. También se describen composiciones farmacéuticas de compuestos de fórmula (I), y métodos para usar tales compuestos y composiciones.
MX2016009621A 2014-01-24 2015-01-22 Derivados de fur0-3-carboxamida y metodos de uso. MX2016009621A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931232P 2014-01-24 2014-01-24
PCT/US2015/012519 WO2015112754A1 (en) 2014-01-24 2015-01-22 Furo-3-carboxamide derivatives and methods of use

Publications (1)

Publication Number Publication Date
MX2016009621A true MX2016009621A (es) 2016-11-17

Family

ID=52469321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009621A MX2016009621A (es) 2014-01-24 2015-01-22 Derivados de fur0-3-carboxamida y metodos de uso.

Country Status (7)

Country Link
US (1) US9777020B2 (es)
EP (1) EP3097095A1 (es)
JP (1) JP2017508729A (es)
CA (1) CA2937074A1 (es)
MX (1) MX2016009621A (es)
SG (1) SG11201605915WA (es)
WO (1) WO2015112754A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160930A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
US10603320B2 (en) * 2017-03-02 2020-03-31 Eli Lilly And Company Compounds useful for inhibiting ROR-gamma-t
HUE054483T2 (hu) * 2017-03-02 2021-09-28 Lilly Co Eli ROR-gamma-T gátlására alkalmas vegyületek
CN107383026B (zh) * 2017-06-29 2019-04-30 武汉药明康德新药开发有限公司 一种7-羟甲基-2,5-二氮杂螺[3,4]辛烷-2-甲酸叔丁酯的合成方法
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
WO2020145369A1 (ja) 2019-01-11 2020-07-16 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体
CN110563726A (zh) * 2019-07-23 2019-12-13 上海合全药业股份有限公司 叔丁基-7,9-二氧亚基-2,6-二氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814161A (pt) * 1997-11-13 2000-09-26 Pfizer Prod Inc Método de sìntese de pirrolamidas
BR0115874A (pt) * 2000-12-04 2003-10-28 Pfizer Prod Inc Sìntese de pirrole-amidas
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
RU2461551C2 (ru) * 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
CN103534257A (zh) * 2011-04-05 2014-01-22 辉瑞有限公司 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物
US9822118B2 (en) * 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors

Also Published As

Publication number Publication date
CA2937074A1 (en) 2015-07-30
SG11201605915WA (en) 2016-08-30
US9777020B2 (en) 2017-10-03
US20150210720A1 (en) 2015-07-30
JP2017508729A (ja) 2017-03-30
EP3097095A1 (en) 2016-11-30
WO2015112754A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
PH12017500089B1 (en) Aldosterone synthase inhibitors
WO2017177004A8 (en) Tertiary amides and method of use
MX2016013329A (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas.
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2017003458A (es) Indazol ureas y metodo de uso.
MY189372A (en) Indole derivatives
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
IN2013MU03838A (es)